Elsevier

European Journal of Cancer

Volume 33, Issue 13, November 1997, Pages 2194-2197
European Journal of Cancer

Original paper
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast

https://doi.org/10.1016/S0959-8049(97)00396-1Get rights and content

Abstract

Chemotherapy given to patients with metastatic carcinoma of the breast is palliative in intent. Longer regimens would be justified if there was a proven prolongation of symptom response or survival. We conducted a randomised trial to assess the survival of patients receiving up to six extra courses of chemotherapy compared with our conventional regimen of six courses. The patients received either VAC, VEC (vincristine, doxorubicin or epirubicin and cyclophosphamide) or MMM (mitozantrone, methotrexate and mitomycin C) therapy. Patients who had stable disease or were responding after six courses of chemotherapy were randomised to either stop or continue treatment for another six courses. Those patients receiving maintenance therapy had a significantly longer duration of response (P <0.02) and a significantly longer progression-free survival (P <0.01). However, there was no survival difference between the two groups. Furthermore, treatment toxicity, which was similar in the two groups, persisted for longer in the maintenance group. These results indicate no clinical advantage for giving maintenance chemotherapy in order to prolong survival of patients with metastatic breast cancer.

References (13)

There are more references available in the full text version of this article.

Cited by (52)

  • The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice

    2020, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    Other studies either did not specify how PFS was defined [71–74], or evaluated the period from randomization until progression of disease including a possible reintroduction of chemotherapy in the ‘short’ treatment arm [75]. Overall, 10 out of 13 individual trials indicated a relevant and significant improvement in PFS with longer durations of chemotherapy [64–68,70,71,73,74,76]. Muss et al evaluated both definitions of PFS and found results were only statistically significantly better for the long arm when looking at the first occurrence of disease progression, not including PFS duration of re-introduction of chemotherapy in the ‘short’ treatment arm [76].

  • Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer

    2013, Breast
    Citation Excerpt :

    Even though current practice guideline is to continue the first-line chemotherapy until disease progression [1], the optimal duration of cytotoxic chemotherapy for MBC is still controversial. There have been several trials to investigate the efficacy of maintenance chemotherapy in MBC [2–11]. These trials showed consistent benefit of maintenance therapy in terms of PFS, but improvement of overall survival (OS) was not observed in most of the trials [5].

  • Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab

    2012, Breast
    Citation Excerpt :

    Metastatic breast cancer is considered a chronic disease, where the aim of treatment is the improvement of quality of life and prolongation of survival. Developments in therapeutic interventions for metastatic breast cancer have led to improvements in time to disease progression, time to treatment failure, quality of life, and overall survival.1–5 Research is now focused on developing novel treatment strategies that might be as effective but less toxic than standard chemotherapy.

View all citing articles on Scopus
View full text